SS‐31 Research Peptide Overview

SS‐31 (also known as MTP‐131) is a synthetic tetrapeptide developed by researcher. It is studied primarily for its ability to target mitochondria directly, stabilize the inner mitochondrial membrane, and improve cellular energy production in preclinical models of aging, cardiac injury, and metabolic disease.

What sets SS‐31 apart from most peptides is how specifically it acts. Rather than broadly suppressing oxidative stress or triggering upstream signaling cascades, it travels directly to the inner mitochondrial membrane and binds to a phospholipid called cardiolipin, which is found almost exclusively in that location. That targeted interaction drives its core effects:

• Cardiolipin stabilization: By binding cardiolipin, SS‐31 preserves the structural integrity of the mitochondrial inner membrane, maintaining the cristae architecture that the electron transport chain depends on for efficient ATP production.

• Reduced reactive oxygen species (ROS): Stabilizing the electron transport chain limits electron leak, which in turn reduces superoxide and other damaging ROS without broadly interfering with normal redox activity.

• Improved ATP synthesis: With less electron leak and better membrane organization, mitochondria in SS‐31 treated cells produce ATP more efficiently, a key finding across cardiac, skeletal muscle, and renal models.

• Cytoprotection during ischemia: By preventing mitochondrial swelling and protecting cristae integrity during periods of low oxygen, SS‐31 has shown consistent protective effects in ischemia‐reperfusion injury models across multiple tissue types.

Integrated Research Applications

SS‐31 has become a go‐to tool for researchers studying mitochondrial dysfunction because it works in so many tissue types where mitochondria are dense and critical. Key research areas include:

• Heart research: This is where most of the SS‐31 work is concentrated. In animal models, it has reduced infarct size, improved heart function after ischemia, and even reversed age‐related stiffening of the heart muscle. It has progressed to clinical trials for Barth syndrome and heart failure with preserved ejection fraction.

• Muscle and aging research: In older animals, SS‐31 has brought mitochondrial energy output closer to what is seen in younger subjects, with improvements in both resting muscle function and recovery. It is a useful compound for studying how energy metabolism changes with age.

• Kidney research: SS‐31 has shown strong protective effects in renal ischemia models, preserving kidney cell structure and reducing oxidative damage during and after blood flow disruption.

• Brain and neurodegenerative research: Studies have looked at SS‐31 in Parkinson's, Alzheimer's, and stroke models, where protecting mitochondrial function in neurons appears to reduce cell death and support recovery.

Analytical Validation, Formulation, and Storage

SS‐31 is supplied as a lyophilized white powder in glass vials at ≥99% purity, verified by HPLC with a batch‐specific certificate of analysis.

Formulation: Lyophilized powder for reconstitution with an appropriate solvent like BAC water, and supplied without dosing instructions of any kind.

Storage follows standard peptide handling practice:

• Store lyophilized vials at or below −20 °C in a cool, dark, dry environment.

• After reconstitution, refrigerate at 2–8 °C, avoid repeated freeze‐thaw cycles, and use within laboratory‐defined timeframes.

NextGenPeps supplies SS-31 as a high purity research peptide intended strictly for controlled laboratory use in vitro or in established animal models, such as murine systems. This compound is not approved as a drug, diagnostic, or dietary ingredient in this context, and is not manufactured, packaged, or marketed for consumption, self experimentation, clinical application, or any use outside properly designed and ethically approved research protocols.